Spolecnost Aptorum Group zahájila studie umožnující IND pro kandidáta na prípravek s malou molekulou ALS-4 pro lécbu infekcí zpusobených bakterií Staphylococcus Aureus vcetne MRSA
Aptorum Group Limited - Class A Ordinary Shares (APM)
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Spolecnost Aptorum Group Limited (burzovní index Nasdaq: APM) ("Aptorum Group"), biofarmaceutická spolecnost, která se venuje vývoji nových lécivých prípravku pro rešení globálních neuspokojených lékarských potreb, oznamuje, že zahájila výzkumné studie umožnující IND nových léku pro prípravek ALS-4, kandidáta na lék s malou molekulou indikovaného k lécbe infekcí zpusobených bakterií Staphylococcus aureus (dále "S. aureus"), vcetne bakterie Staphylococcus aureus rezistentní proti meticilinu (MRSA, tj. jednoho z bežne známých "super-bugu") na základe nového prístupu k nicení viru.Kandidát ALS-4 vykazuje dobrý pokrok, a prostrednictvím jmenované smluvní organizace pro výzkum v Severní Americe (CRO) byla dokoncena první série toxikologických studií GLP. Kandidát ALS-4 zejména neprojevil v testech Ames in vitro žádnou mutagenitu. Vývoj prípravku ALS-4 pokracuje dobre, a spolecnost si klade za cíl predložit související IND v první polovine roku 2020. V Severní
Show less
Read more
Impact Snapshot
Event Time:
APM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APM alerts
High impacting Aptorum Group Limited - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APM
News
- Aptorum Group (NASDAQ:APM) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference [Yahoo! Finance]Yahoo! Finance
- DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 ConferenceGlobeNewswire
- Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Aptorum Group Limited Announces Up To $6 Million Registered Direct OfferingGlobeNewswire
APM
Sec Filings
- 12/4/25 - Form EFFECT
- 11/18/25 - Form DEL
- 11/17/25 - Form F-1
- APM's page on the SEC website